Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527150 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00527150 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 48 participants.
The verdict
NCT00527150, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating multiple oral doses of varenicline AMT 8 controlled release formulation for 14 days in adult smokers.
Interventions
- DRUG Varenicline Tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00527150
The ClinicalTrials.gov registry entry for NCT00527150 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Varenicline Tartrate is the first listed.
NCT00527150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00527150 about?
NCT00527150 is a clinical study titled "Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers". The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating multiple oral doses of varenicline AMT 8 controlled release formulation for 14 days in adult smokers.
What is the current status of trial NCT00527150?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2007-10. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00527150?
The interventions under investigation include: Varenicline Tartrate (DRUG).
Who is sponsoring clinical trial NCT00527150?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.